XML 62 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenue $ 29,621 $ 46,803
License Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue 0 9,649
Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue 1,948 18,401
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue 1,395 6,452
AstraZeneca Agreements [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue 159,000 89,100
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue 0 2,649
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]    
Disaggregation of Revenue [Line Items]    
Total revenue $ 418 $ 9,473